Current Price
Target Price
Analyst Sentiment
5 ratings: Buy
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company is headquartered...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2026 | FY 2026 | FY 2026 | FY 2027 |
|---|---|---|---|---|
| $2.69 | $-0.60 | $-0.24 | $-1.61 | |
| 0 | 0 | 0 | 0 | |
| — | -35.7% | +14.3% | +0.6% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LLycia Ther... | LYCA | $1.63B | — | — | — | -762.00% | — | — |
| 2. | KKardigan I... | KARD | $1.29B | — | 2.10 | — | — | — | — |
| 3. | KKorsana Bi... | KRSA | $1.44B | — | 3.66 | — | — | — | — |
| 4. | RRapport Th... | RAPP | $1.55B | — | 3.96 | — | -838.00% | -33.30% | — |
| 5. | LLB Pharmac... | LBRX | $1.39B | — | 3.33 | — | — | -38.80% | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - | - | - | - |
| 0.01 | 0.03 | 59.29 | 6.98 | 15.05 | 15.88 | 30.15 | |
EBIT | -0.01 | -0.03 | -59.29 | -6.98 | -15.05 | -15.88 | -30.15 |
OPM % | - | - | - | - | - | - | - |
Non-Operating Income | -0.09 | -0.35 | 0.17 | 0.53 | 0.77 | 0.89 | 3.65 |
PBT | -0.1 | -0.38 | -59.12 | -6.45 | -14.28 | -14.99 | -26.5 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - |
Net Income | -0.1 | -0.38 | -59.12 | -6.45 | -14.28 | -14.99 | -26.5 |
NPM % | - | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2025 |
|---|---|
Revenue | 0 |
COGS | 0 |
Gross Profit | 0 |
Gross Profit % | - |
| 4.5 | |
EBIT | -4.5 |
OPM % | - |
Non-Operating Income | -61.55 |
PBT | -66.05 |
Income Tax | 0 |
Tax Rate % | - |
Net Income | -66.05 |
NPM % | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2025 |
|---|---|
| 89.16 | |
| 0 | |
| 0 | |
| 0.12 | |
| 0.07 | |
Total Assets | 89.35 |
| 0 | |
| -65.87 | |
| 0 | |
| 1.06 | |
| 154.16 | |
Total Liabilities | 89.35 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2025 |
|---|---|
| -2.01 | |
| 0 | |
| 124.74 | |
Net CFNet Cash Flow | 122.73 |
FCFFree Cash Flow | -35.58 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2025 |
|---|---|
| - | |
| - | |
| 17.03 | |
| - | |
Cash Conversion | 0.03 |
Payout Ratio | - |
| - | |
| - | |
| - | |
| 2.00 | |
| - | |
| - | |
| - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Braveheart Bio Inc, from SEC filings
Schedule 13D / 13G filers (5%+), plus stakes Braveheart Bio Inc holds in others · open a holder to see each filing
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Holding company | DE | 7,374,365 | 8.20% | SC 13G · 5 Nov 2026 | |
| Corporation | F4 | 7,420,091 | 8.20% | SC 13G · 9 Nov 2026 | |
| Partnership | DE | 4,976,457 | 5.50% | SC 13G · 14 Aug 2026 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Month | Insiders | Shares sold | Value sold | Shares bought | Value bought | Awards, tax, gifts |
|---|---|---|---|---|---|---|
| 11 | — | — | 8,835,275 | $159.0M | 51,940,638 |
Form 4, filed within two business days of each trade. Sales and purchases are open-market; awards, tax withholding, gifts and option exercises are grouped. Amended filings are left out so a restated trade isn't counted twice.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 5,153,595 | +5.1% | 19.63 | |
| 15 Oct 2026 | 4,905,289 | +18.8% | 11.76 | |
| 30 Sep 2026 | 4,128,974 | +67.8% | 5.10 | |
| 15 Sep 2026 | 2,461,086 | +76.1% | 7.49 | |
| 31 Aug 2026 | 1,397,189 | +64.8% | 5.59 | |
| 14 Aug 2026 | 847,773 | 1.30 |
FINRA consolidated short interest, reported twice a month for every US listing.
Braveheart Bio Inc's SEC filings and earnings call transcripts
What recent news says about Braveheart Bio Inc, scored for sentiment.